TumorDiagnostik & Therapie, Inhaltsverzeichnis TumorDiagnostik & Therapie 2017; 38(06): 368-372DOI: 10.1055/s-0043-107672 Schwerpunkt Tumoren der Nieren und ableitenden Harnwege © Georg Thieme Verlag KG Stuttgart · New YorkChemotherapie des Harnblasenkarzinoms Tobias Steinwender , Peter HammerArtikel empfehlen Abstract Artikel einzeln kaufen Die seit Jahren etablierte cisplatinhaltige Chemotherapie spielt beim fortgeschrittenen und metastasierten Harnblasenkarzinom weiterhin eine wichtige Rolle. Aktuelle Studienergebnisse mit verschiedenen Immuncheckpoint-Inhibitoren sind vielversprechend, sodass diese Substanzen die therapeutischen Möglichkeiten erweitern. Volltext Referenzen Literatur 1 Zentrum für Krebsregisterdaten im Robert Koch-Institut (Hrsg). Bericht zum Krebsgeschehen in Deutschland 2016. Berlin: 2016 2 Humphrey PA, Moch H, Cubilla AL. et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol 2016; 70: 106-119 3 S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms Langversion1.1, November 2016, AWMF-Registernummer: 032/038OL. 4 Abern MR, Owusu RA, Anderson MR. et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw 2013; 11: 477-484 5 Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-1970 6 Kamat AM, Witjes JA, Brausi M. et al. Defining and treating the spectrum of intermediate risknonmuscle invasive bladder cancer. J Urol 2014; 192: 305-315 7 Retz M, Gschwend J. Medikamentöse Tumortherapie in der Uroonkologie. Berlin Heidelberg: Springer-Verlag; 2010 2. Auflage. 8 http://www.auanet.org/guidelines/muscle-invasive-bladder-cancer-new-(2017) 9 Reardon ZD, Patel SG, Zaid HB. et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: A sign of changing tides. Eur Urol 2015; 67: 165-170 10 Sternberg CN, Yagoda A, Scher HI. et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458 11 von der Maase H, Hansen SW, Roberts JT. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077 12 Winquist E, Kirchner TS, Segal R. et al. Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004; 171: 561-569 13 Svatek RS, Shariat SF, Lasky RE. et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010; 16: 4461-4467 14 Sternberg CN, Skoneczna I, Kerst JM. et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015; 16: 76-86 15 James ND, Hussain SA, Hall E. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366: 1477-1488 16 Nagao K. The efficacy of trimodal chemoradiotherapy as a bladder-preserving strategy for muscle invasive bladder cancer. J Urol 2017 in press 17 Loehrer Sr PJ, Einhorn LH, Elson PJ. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066-1067 18 Bellmunt J, von der Maase H, Mead GM. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-1113 19 De Santis M, Bellmunt J, Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199 20 Galsky MD, Hahn NM, Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011; 29: 2432-2438 21 von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003; 3: 11-19 22 Bellmunt J, Ribas A, Eres N. et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966-1972 23 Bellmunt J, Théodore C, Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461 24 Ning YM, Suzman D, Maher VE. et al. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist 2017; 22 [Epub ahead of print] 25 Roche Media Release, Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer. 26 Sharma P, Callahan MK, Bono P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016; 17: 1590-1598 27 Massard C, Gordon MS, Sharma S. et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 2016; 34: 3119-3125 28 Heery CR, O'Sullivan-Coyne G, Madan RA. et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017; 18: 587-598 29 Bellmunt J, de Wit R, Vaughn DJ. et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376: 1015-1026